

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Search of New Cytotoxic Crude Materials Against Human Oral Squamous Cell Carcinoma Using ^1H NMR-based Metabolomics

RYUICHIRO SUZUKI¹, SHINPEI MATSUNO¹, HIROSHI SAKAGAMI²,
YOSHIHITO OKADA³ and YOSHIAKI SHIRATAKI¹

¹*Faculty of Pharmaceutical Sciences, Josai University, Saitama, Japan;*

²*Division of Pharmacology, Meikai University School of Dentistry, Saitama, Japan;*

³*Meiji Pharmaceutical University, Kiyose, Tokyo, Japan*

Reprinted from

ANTICANCER RESEARCH 34: 4117-4120 (2014)

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005

ISSN (online): 1791-7530

Editorial Board

P.A. ABRAHAMSSON, Malmö, Sweden
B. B. AGGARWAL, Houston, TX, USA
T. AKIMOTO, Kashiwa, Chiba, Japan
A. ARGIRIS, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
R. C. BAST, Houston, TX, USA
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicetre, France
Y. BECKER, Jerusalem, Israel
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
D. D. BIGNER, Durham, NC, USA
A. BÖCKING, Düsseldorf, Germany
G. BONADONNA, Milan, Italy
F. T. BOSMAN, Lausanne, Switzerland
G. BROICH, Monza, Italy
J. M. BROWN, Stanford, CA, USA
Ø. S. BRULAND, Oslo, Norway
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
E. DE CLERCQ, Leuven, Belgium
W. DE LOECKER, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMANDOPOULOS, Boston, MA, USA
D. W. FELSHER, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
B. FUCHS, Zurich, Switzerland
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
J. H. GESCHWIND, Baltimore, MD, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
R. H. GOLDFARB, Saranac Lake, NY, USA
S. HAMMARSTRÖM, Umeå, Sweden
I. HELLSTRÖM, Seattle, WA, USA
L. HELSON, Quakertown, PA, USA
R. M. HOFFMAN, San Diego, CA, USA
K.-S. JEONG, Daegu, South Korea
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
B. KAINA, Mainz, Germany
P. -L. KELLOKUMPU-LEHTINEN, Tampere, Finland
B. K. KEPPLER, Vienna, Austria
D. G. KIEBACK, Riesa (Dresden), Germany
R. KLAPDOR, Hamburg, Germany
U. R. KLEEBERG, Hamburg, Germany
P. KLEIHUES, Zürich, Switzerland
E. KLEIN, Stockholm, Sweden
S. D. KOTTARIDIS, Athens, Greece

G. R. F. KRUEGER, Köln, Germany
D. W. KUFE, Boston, MA, USA
Pat M. KUMAR, Manchester, UK
Shant KUMAR, Manchester, UK
M. KUROKI, Fukuoka, Japan
O. D. LAERUM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umeå, Sweden
H. T. LYNCH, Omaha, NE, USA
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skövde, Sweden
S. MITRA, Houston, TX, USA
M. MUELLER, Heidelberg, Germany
F. M. MUGGIA, New York, NY, USA
M. J. MURPHY, Jr., Dayton, OH, USA
M. NAMIKI, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J.L. PERSSON, Malmö, Sweden
S. PESTKA, Piscataway, NJ, USA
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATSOUKAS, Norfolk, VA, USA
F. PODO, Rome, Italy
A. POLLIACK, Jerusalem, Israel
G. REBEL, Strasbourg, France
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELLI, Rome, Italy
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
G.-I. SOMA, Tokushima, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
B. TOTH, Omaha, NE, USA
P. M. UELAND, Bergen, Norway
H. VAN VLIJBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Duarte, CA, USA
M.R.I. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA

J. G. DELINASIOS, Athens, Greece
 Managing Editor

G. J. DELINASIOS, Athens, Greece
 Assistant Managing Editor and
 Executive Publisher

E. ILIADIS, Athens, Greece
 Production Editor

Editorial Office: International Institute of Anticancer Research, 1st km
 Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014,
 Greece. Tel / Fax: +30-22950-53389.

E-mails: Editorial Office: journals@iia-anticancer.org
 Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research.

For more information about ANTICANCER RESEARCH, IAR and the Conferences, please visit the IAR website: www.iia-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

Annual Subscription Rates 2014 per volume: Institutional subscription Euro 1,650.00 - print or online. Personal subscription Euro 780.00 - print or online. Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-33, 1981-2013) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. Cheques should be made payable to J.G. Delinasios, Executive Publisher of Anticancer Research, Athens, Greece, and should be sent to the Editorial Office.

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2014 \$2.00 +0.40.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2014, International Institute of Anticancer Research
 (Dr. John G. Delinasios), All rights reserved.
 D.T.P. BY IAR
 PRINTED BY ENTYP0, ATHENS, GREECE
 PRINTED ON ACID-FREE PAPER

Search of New Cytotoxic Crude Materials Against Human Oral Squamous Cell Carcinoma Using ^1H NMR-based Metabolomics

RYUICHIRO SUZUKI¹, SHINPEI MATSUNO¹, HIROSHI SAKAGAMI²,
YOSHIHITO OKADA³ and YOSHIAKI SHIRATAKI¹

¹Faculty of Pharmaceutical Sciences, Josai University, Saitama, Japan;

²Division of Pharmacology, Meikai University School of Dentistry, Saitama, Japan;

³Meiji Pharmaceutical University, Kiyose, Tokyo, Japan

Abstract. *Background:* The 5-year survival rate of the oral cancer patients has remained at approximately the 50% level during the past 30 years, possibly due to the poor tumor-selectivity of conventional anticancer drugs. This prompted us to search new plant extracts that have higher cytotoxicity against cancer cells than normal cells. *Materials and Methods:* Two human oral squamous cell carcinoma cell lines (HSC-2 and HSC-4) and two normal oral cells (gingival and periodontal ligament fibroblasts; HGF and HPLF) were incubated for 48 h with various concentrations of crude plant extract and the viable cell number was determined by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. The 50% cytotoxic concentration (CC_{50}) was determined from the dose-response curve. Tumor-specificity (TS) was determined by the following equation: $\text{TS} = \text{mean } \text{CC}_{50}(\text{normal cells}) / \text{mean } \text{CC}_{50}(\text{cancer cell lines})$. Metabolic profiling techniques based on ^1H nuclear magnetic resonance (NMR) were applied to gain the chemical structural insight for cytotoxicity induction. *Results:* Among 24 plant extracts, *Camptotheca acuminata* leaf, a well-known source for camptothecin, showed the highest TS value (88.3), followed by *Vitis s.p.p.* (>3.5), *Sasa veitchii* (>2.3) and *Phellodendron amurense* (>2.1), whereas other plant extracts showed much lower TS value (<2). These cytotoxic extracts made cluster on principal component analysis (PCA) score plot. *Conclusion:* The TS value determined by the present method seems to reflect the anti-tumor potential of each plant extract, while a part of the cytotoxic compounds present in these extracts may have common chemical structures.

Oral and oropharyngeal squamous cell carcinoma represents a large, worldwide health burden with approximately 350,000 cases diagnosed annually (1). Most oral cancers are diagnosed at an advanced stage accompanied by metastasis to the lymph nodes located under the jaw and in the neck. Possibly due to the late diagnosis of this disease or the poor-tumor selectivity of conventional anti-tumor agents, the 5-year survival rate of patients has remained at the level of approximately 50% during the past 30 years. For squamous cell carcinoma and most other types of oral cancer, surgery and radiation remain as the sole therapy (2). Moreover, surgery for oral cancers can be disfiguring and psychologically-traumatic. Therefore, the development of new treatment strategies and the early diagnosis of oral cancer are of great importance (3). We have been searching for new candidate materials derived from natural sources to treat oral cancer. Actually, we herein investigated the effects of crude plant extracts on the growth of oral normal (human gingival fibroblast, HGF; periodontal ligament fibroblast, HPLF) and tumor cells (oral squamous cell carcinoma HSC-2 and HSC-4).

Metabolic profiling techniques were used to find possible correlations between the structural factors of a compound and its biological activity (4, 5). Loading plot analysis provides a useful strategy for the identification of biological compounds. Nuclear magnetic resonance (NMR) is a powerful method for such analysis because it allows the simultaneous detection of diverse groups of primary and secondary metabolites (6). In addition, NMR can give much more structural information about metabolites than other analytical techniques such as mass spectrometry (MS). We have already reported the utilities of a metabolic profiling method for evaluation of biological activities and growth area of crude drugs (7, 8). In this study, we used ^1H NMR-based metabolic analysis to evaluate cytotoxicity of crude plant extracts against oral squamous cell carcinoma and to acquire chemical structural information of active compounds included in cytotoxic materials.

Correspondence to: Professor Yoshiaki Shirataki, Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai Sakado, Saitama 350-0295, Japan. Tel: +81 492717053, Fax: +81 492717984, e-mail: shiratak@josai.ac.jp

Key Words: Crude drugs, cytotoxicity, ^1H NMR metabolomics.

Table I. Cytotoxicity of crude plant extracts (#1-24). The cells were incubated for 48 h without or with different concentrations of test samples and the 50% cytotoxic concentration (CC₅₀) value was determined by MTT. Each value represents the mean of triplicate assays. Note about No. 13-15 including 17 and 18: these samples were collected in different places, respectively.

No.	Scientific name	Part	CC ₅₀ (μg/ml)						
			Normal cells		Oral squamous cell carcinoma				
			HGF	HPLF	Mean±S.D.	Mean±S.D.	Mean±S.D.	Mean±S.D.	TS
					(n=4)	HSC-2	HSC-4	(n=4)	
1	<i>Odontioda</i> Marie Noel ‘Velano’	Leaf	289	305	297±16	278	322	300±45	1.0
2	<i>Odontioda</i> Marie Noel ‘Velano’	Bulb	265	302	283±24	313	297	305±42	0.9
3	<i>Odontioda</i> Marie Noel ‘Velano’	Root	125	157	141±20	105	84	95±13	1.5
4	<i>Odontoglossum</i> Harvengtense ‘Tutu’	Leaf	271	302	286±19	277	272	274±19	1.0
5	<i>Odontoglossum</i> Harvengtense ‘Tutu’	Bulb	521	485	503±43	>500	400	>450	<1.1
6	<i>Odontoglossum</i> Harvengtense ‘Tutu’	Root	157	207	182±47	141	128	135±17	1.3
7	<i>Pandanus amaryllifolius</i>	Leaf	335	357	346±157	258	246	252±35	1.4
8	<i>Daucus carota</i>	Leaf	8	230	119±133	108	132	120±50	1.0
9	<i>Vitis</i> spp	Root	370	>500	>435	128	118	123±9	>3.5
10	<i>Camptotheca acuminata</i>	Leaf	283	335	309±30	4.3	2	3.5±1.6	88.3
11	<i>Rhinacanthus nasutus</i>	Root	23	209	116±113	290	226	258±84	0.4
12	<i>Phellodendron amurense</i>	Bark	>500	>500	>500	300	244	272±37	>1.8
13	<i>Sophora flavescens</i>	Root	>500	>500	>500	>428	423	>425	><1.2
14	<i>Sophora flavescens</i>	Root	148	183	165±23	116	138	127±16	1.3
15	<i>Sophora flavescens</i>	Root	>500	>500	>500	>426	317	372±87>	1.3
16	<i>Myrica rubra</i>	Twig	58	74	66±17	83	52	67±27	1.0
17	<i>Myrica rubra</i>	Leaf	<3.9	7	<5	23	14	18±5	<0.3
18	<i>Myrica rubra</i>	Leaf	<3.9	24	<14	111	89	100±59	<0.1
19	<i>Nandina domestica</i>	Leaf	316	278	297±40	228	246	240±59	1.2
20	<i>Euptelea polyandra</i>	Leaf	103	88	95±13	97	108	102±20	0.9
21	<i>Sasa veitchii</i>	Leaf	415	>500	>458	198	197	197±12	>2.3
22	<i>Theobroma cacao</i>	Fruit	452	>500	>476	>500	414	>457	><1.0
23	<i>Phellodendron amurense</i>	Bark	>443	>500	>500	183	293	238±71	>2.1
24	<i>Actinidia polygama</i>	Root	>500	>500	>500	>500	>500	>500	><1.0

Concentrations used: 0, 3.9, 7.8, 15.6, 31.25, 62.5, 125, 250, 500 μg/ml of each sample.

Materials and Methods

Materials. The following chemicals and reagents were obtained from the indicated companies: Dulbecco’s modified Eagle medium (DMEM) (Gibco BRL, Grand Island, NY, USA); fetal bovine serum (FBS) (JRH Bioscience, Lenexa, KS, USA); 5-fluorouracil (5-FU) (Kyowa, Tokyo, Japan); dimethyl sulfoxide (DMSO) (Wako Pure Chem. Inc., Osaka, Japan); DMSO-*d*₆ (Cambridge Isotope Laboratories, Inc., MA, USA)

Plant materials. Crude plant extracts used in this study are listed in Table I. These extracts have been already prepared and employed for various screenings in our laboratory. All extracts were stored at –30°C before using. The original plants were mainly collected in various places in Japan. The specimens were proved and identified by Dr. Y. Shirataki and voucher specimens were also deposited in the Department of Pharmacognosy and Natural Medicines of Josai University.

NMR spectroscopy. ¹H NMR spectra were recorded at room temperature on a 400 MHz Agilent-400MR-vnmrs 400 spectrometer

(Agilent Technologies, CA, USA). Each spectrum consisted of 65,536 complex data points and a spectral width of 6,410.3Hz, obtained by 16 scans with a repetition time of 5.0 sec and a relaxation delay of 1.50 sec per scan. The detection pulse flip angle was set at 45°.

NMR data reduction procedures and pattern recognition analysis. Each NMR spectrum was regimented into 375 regions, 0.04 part per million (ppm) wide, over the range –1.50 to 13.5 ppm. Each segment of the spectral regions (bucket) was integrated. Any integrated regions from 2.45 to 2.55 ppm that contained solvent signals were eliminated from the data table and then the total data were reduced to 372 regions. The remaining integral values of each spectrum were normalized over 100 total summed integrals to compensate for any differences in concentration between crude drug extracts. Spectral processing was performed using ALICE 2 for Metabolome version 5.0 software (JEOL Ltd., Akishima, Tokyo, Japan).

Preparation of crude drug extracts. Twenty-four kinds of crude plant extracts were prepared by extracting with MeOH under reflux




Figure 1. The ^1H NMR spectra were subjected to principal component analysis (PCA). PCA score plot of PC1-PC2, in which 372 variables were equally accounted for in the data sets. The scores of PC1 and PC2 were 46.4, 31.8%, respectively. The circled dots show the sample exhibiting high TS value.

for 3 h to give the methanolic extracts. These extracts were completely dried *in vacuo* and residues were dissolved in $\text{DMSO}-d_6$ at 10 mg/ml in concentration for ^1H NMR measurement and dissolved in DMSO for cytotoxic evaluation.

Cell culture. Human oral squamous cell carcinoma cell lines (HSC-2, HSC-4) were purchased from Riken Cell Bank, Tsukuba, Japan. Normal human oral cells, gingival fibroblast (HGF) and periodontal ligament fibroblast (HPLF), were prepared from periodontal tissues, according to the guideline of the Intramural Ethic Committee (No. A0808), after obtaining the informed consent from a 12-year-old patient at the Meikai University Hospital (9). Since normal oral cells have a limited lifespan of 43-47 population doubling levels (PDL) (9), the cells at 8-15 PDL were used in this study. All the cells were cultured in DMEM medium supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin G and 100 $\mu\text{g}/\text{ml}$ streptomycin sulfate. The normal cells were detached by 0.25% trypsin-0.025% EDTA-2Na in phosphate-buffered saline (PBS) without Mg^{2+} and Ca^{2+} (PBS(-)) and subcultured at a 1 : 4 split ratio once a week with a medium change in between the subcultures.

Assay for cytotoxic activity. The cells (3×10^3 cells/well, 0.1 ml/well) were seeded in 96-microwell plates (Becton Dickinson and Company, Franklin Lakes, NJ, USA) and incubated for 48 h to allow cell attachment. Near-confluent cells were treated for 48 h with different

concentrations of the test compounds in a fresh medium. The relative viable cell number of adherent cells was then determined by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (10). In brief, control and sample-treated cells were incubated for 4 h with 0.2 mg/ml of MTT in the culture medium. After removing the medium, the reaction product, formazan, was extracted with DMSO and the absorbance (the relative viable cell number) was measured at 540 nm by a microplate reader (Multiskan Bichromatic Labsystems, Helsinki, Finland). The 50% cytotoxic concentration (CC_{50}) was determined from the dose-response curve. The tumor specificity index (TS) was calculated by the following equation: $\text{TS} = \text{mean CC}_{50} (\text{normal cells}) / \text{mean CC}_{50} (\text{all tumor cell lines})$.

Results

Cytotoxicity. Several kinds of crude plant extracts showed higher cytotoxicity against human oral squamous cell carcinoma compared with human oral normal cells, yielding the tumor-specificity value of 1.0-88.3 (Table I). The extract of #10 (*Camptotheca acuminata*) showed the highest tumor-specificity, followed by #9 > #21 > #3 > #6 > #16.

^1H NMR metabolomics. To give the chemical structural feature of the active components, the crude plant extracts

were subjected to NMR-based metabolomics. The ^1H NMR spectra were subjected to principal component analysis (PCA) (Figure 1). All 372 variables in the bucketed regions (see Materials and Methods section) were equally accounted for in the data sets. The PCA score plot of principal component (PC) 1 (the greatest variance in the data) and PC2 (the second greatest variance in the data, orthogonal with PC1) showed that the crude plant extracts showing high TS value were gathered on PCA score plot (Figure 1, circled dots indicated the sample showing high TS value). The scores of PC1 and PC2 were 46.4, 31.8%, respectively.

Discussion

The present study demonstrated that some methanolic plant extracts showed tumor-specific cytotoxicity ($\text{TS}=1.0\text{-}88.3$) (Table I). Among these extracts, the extract of #10 (*Camptotheca acuminata*) showed the highest tumor specificity ($\text{TS}=88.3$). *C. acuminata* belongs to Nyssaceae and distributed in the center of South China. It is well-known that *C. acuminata* includes camptothecin, which has been the lead compound for irinotecan. Irinotecan shows tumor-specific cytotoxicity based on the inhibition of topoisomerase and is used for the clinical treatment of lung and cervical cancer. The present study demonstrated that the extract of *C. acuminata* indicated the highest TS value, in agreement with our recent report that camptothecin and SN-38, active metabolite of irinotecan, showed the TS value of 2561 and 808, respectively (11). This indicates that the TS value determined by the present method seems to reflect the anti-tumor potential of each plant extract, and may be a useful index for searching the new anti-tumor agents, regardless of the cell types [epithelia origin for oral squamous cell carcinoma (HSC-2, HSC-4) and mesenchymal origin for normal oral cells (HGF, HPLF)]. Although both cytotoxicity and TS values are inferior to those of #10, the extracts of #9 (*Vitis* spp), # 21 (*Sasa veitchii*), #3 (*Odontioda* Marie Noel 'Velano'), #6 (*Odontoglossum Harvengtense* 'Tutu') and #16 (*Myrica rubra*) indicated slightly higher cytotoxicity against human oral squamous cell carcinoma yielding modulate TS values.

The values of PC1 and PC2 were used to give the information concerning chemical structure of active components in cytotoxic crude plant extracts. The score sum of PC1 and PC2 was 78.2%, which was sufficient to identify active components. Cytotoxic crude plant extracts indicating modulate TS value formed a cluster on PCA score plot. These results demonstrated that these extracts could contain common compounds with similar structure(s) for expressing

cytotoxicity against tumor cells. Loading plot analysis and direct comparison of ^1H NMR spectra indicated that aromatic signals on ^1H NMR spectrum were detected commonly in cytotoxic extracts. Based on these results, we are planning to isolate and purify the active compounds and to elucidate those structures included in cytotoxic crude extracts.

References

- 1 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun JM: Cancer statistics, 2008. *CA Cancer J Clin* 58: 71-96, 2008.
- 2 Hsu S, Singh B and Schuster G: Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. *Oral Oncol* 40: 461-473, 2004.
- 3 Ozi MJ, Suffredini BI, Paciencia M, Frana AS and Dib LL: *In vitro* cytotoxic effects of Brazilian plant extracts on squamous cell carcinoma of the oral cavity. *Braz Oral Res* 25: 519-525, 2011.
- 4 Fujimura Y, Kurihara K, Ida M, Kosaka R, Miura D, Wariishi H, Maeda-Yamamoto M, Nesumi A, Saito T, Kanda T, Yamada K and Tachibana H: Metabolomics-driven nutraceutical evaluation of diverse green tea cultivars. *PLoS ONE* 6: e23426, 2011.
- 5 Ohno A, Oka K, Sakuma C, Okuda H and Fukuhara K: Characterization of tea cultivated at four different altitudes using ^1H NMR analysis coupled with multivariate statistics. *J Agric Food Chem* 59: 5181-5187, 2011.
- 6 Verpoorte R, Choi HY, Mustafa RN and Kim KH: Metabolomics: back to basics. *Phytochem Rev* 7: 525-537, 2008.
- 7 Suzuki R, Hasuiki Y, Hirabayashi M, Fukuda T, Okada Y and Shirataki Y: Identification of a xanthine oxidase-inhibitory component from *Sophora flavescens* using NMR-based metabolomics. *Nat Prod Commun* 8: 1409-1412, 2013.
- 8 Suzuki R, Ikeda Y, Yamamoto A, Saima T, Fujita T, Fukuda T, Fukuda E, Baba M, Okada Y and Shirataki Y: Classification using NMR-based metabolomics of *Sophora flavescens* growing in Japan and China. *Nat Prod Commun* 7: 1453-1455, 2012.
- 9 Kantoh K, Ono M, Nakamura Y, Nakamura Y, Hashimoto K, Sakagami H and Wakabayashi H: Hormetic and anti-radiation effects of tropolone-related compounds. *In Vivo* 24: 843-852, 2010.
- 10 Masuda Y, Ueda J, Tamura M, Sakagami H, Tomomura M, Tomomura A and Shirataki Y: Diverse biological activity of a Harvengtens 'Tutu' bulb extracts. *In Vivo* 25: 381-386, 2011.
- 11 Tamura N, Hirano K, Kishino K, Hashimoto K, Amano O, Shimada J and Sakagami H: Analysis of type of cell death induced by topoisomerase inhibitors SN-38 in human oral squamous cell carcinoma cell line. *Anticancer Res* 32: 4823-4832, 2012.

Received April 29, 2014

Revised June 13, 2014

Accepted June 16, 2014

Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.